Mineralys Therapeutics, Inc. (MLYS)
NASDAQ: MLYS · Real-Time Price · USD
26.68
+0.34 (1.29%)
At close: Jun 26, 2026, 4:00 PM EDT
26.55
-0.13 (-0.49%)
Pre-market: Jun 29, 2026, 6:29 AM EDT
Mineralys Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Mineralys Therapeutics stock have an average target of 51.17, with a low estimate of 42 and a high estimate of 56. The average target predicts an increase of 91.79% from the current stock price of 26.68.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Mineralys Therapeutics stock from 10 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Mar '26 | Apr '26 | May '26 | Jun '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 8 | 8 | 8 | 9 | 9 | 9 |
| Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 9 | 9 | 9 | 10 | 10 | 10 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Goldman Sachs | Goldman Sachs | Buy Maintains $49 → $42 | Buy | Maintains | $49 → $42 | +57.42% | Jun 4, 2026 |
| LifeSci Capital | LifeSci Capital | Buy Reiterates $44 → $54 | Buy | Reiterates | $44 → $54 | +102.40% | Jun 1, 2026 |
| H.C. Wainwright | H.C. Wainwright | Buy Reiterates $56 | Buy | Reiterates | $56 | +109.90% | Jun 1, 2026 |
| Guggenheim | Guggenheim | Buy Maintains $48 | Buy | Maintains | $48 | +79.91% | May 19, 2026 |
| Bank of America Securities | Bank of America Securities | Buy Maintains n/a | Buy | Maintains | n/a | n/a | May 7, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
121.38M
EPS This Year
-2.24
from -2.29
EPS Next Year
-2.10
from -2.24
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | n/a | 405.8M | |
| Avg | n/a | 121.4M | |
| Low | n/a | 31.8M |
Revenue Growth
| Revenue Growth | 2027 | 2028 |
|---|---|---|
| High | - | 195.3% |
| Avg | - | 109.8% |
| Low | - | 9.6% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | -2.24 | -2.10 | |
| Low | - | - |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.